SLC5A2 and chronic kidney disease: Notably, overall eGFR remained stable during the treatment period, and LN patients with a baseline eGFR <90 mL/min/1.73 m2 demonstrated an improved eGFR slope over 6 months, suggesting a potential renal protective effect of SGLT2 inhibitors in LN patients with pre-existing renal impairment (CKD stage 2 or higher).